Cerdulatinib hydrochloride
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with potent activity against JAK1, JAK2, JAK3, TYK2, and Syk, as well as 19 other kinases. It is utilized in preclinical research for investigating hematological malignancies and autoimmune disorders in both in vitro and in vivo models.
Product Specifications
CAS Number
1369761-01-2
Product Name Alternative
Dual, autoimmune, ARK5, B-cell, cFms, c-Fms, MLK1, MST1, JAK, Hippo pathway, Hippopathway, Tyrosine Kinases, TyrosineKinases, Tyk2, Syk, PRT 062070, PRT 062070 Hydrochloride, PRT 2070, PRT 2070 Hydrochloride, PRT-062070, PRT062070 hydrochloride, PRT-062070 Hydrochloride, PRT-2070, PRT2070 hydrochloride, PRT-2070 Hydrochloride
Field of Research
Cardiovascular Research, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology
Purity
99.23% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.07 mM) ; DMSO:4.82 mg/mL (10 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
Cl.CCS (=O) (=O) N1CCN (CC1) c1ccc (Nc2ncc (C (N) =O) c (NC3CC3) n2) cc1
Molecular Formula
C20H28ClN7O3S
Molecular Weight
482
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog